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Abstract
Background: Combination antiretroviral (AR) therapy continues to be the mainstay for HIV
treatment. However, antiretroviral drug nonadherence can lead to the development of resistance
and treatment failure. We have designed nanoparticles (NP) that contain three AR drugs and
characterized the size, shape, and surface charge. Additionally, we investigated the in vitro release
of the AR drugs from the NP using peripheral blood mononuclear cells (PBMCs).
Methods: Poly-(lactic-co-glycolic acid) (PLGA) nanoparticles (NPs) containing ritonavir (RTV),
lopinavir (LPV), and efavirenz (EFV) were fabricated using multiple emulsion-solvent evaporation
procedure. The nanoparticles were characterized by electron microscopy and zeta potential for
size, shape, and charge. The intracellular concentration of AR drugs was determined over 28 days
from NPs incubated with PBMCs. Macrophages were imaged by fluorescent microscopy and flow
cytometry after incubation with fluorescent NPs. Finally, macrophage cytotoxicity was determined
by MTT assay.
Results: Nanoparticle size averaged 262 ± 83.9 nm and zeta potential -11.4 ± 2.4. AR loading
averaged 4% (w/v). Antiretroviral drug levels were determined in PBMCs after 100 μg of NP in 75
μL PBS was added to media. Intracellular peak AR levels from NPs (day 4) were RTV 2.5 ± 1.1; LPV
4.1 ± 2.0; and EFV 10.6 ± 2.7 μg and continued until day 28 (all AR ≥ 0.9 μg). Free drugs (25 μg of
each drug in 25 μL ethanol) added to PBMCs served as control were eliminated by 2 days.
Fluorescence microscopy and flow cytometry demonstrated phagocytosis of NP into monocytes-
derived macrophages (MDMs). Cellular MTT assay performed on MDMs demonstrated that NPs
are not significantly cytotoxic.
Conclusion:  These results demonstrated AR NPs could be fabricated containing three
antiretroviral drugs (RTV, LPV, EFV). Sustained release of AR from PLGA NP show high drug levels
in PBMCs until day 28 without cytotoxicity.
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Background
An estimated 36 million people are infected with human
immunodeficiency type-1 (HIV-1) worldwide [1]. The
majority of infected people live in the developing world
with limited treatment resources. Antiretroviral (AR) ther-
apy has significantly reduced HIV-1 disease morbidity and
improved life expectancy. However, the economics of
drug treatment, treatment failures due to the development
of resistance, and limited global access has prevented
world-wide utility of AR therapy [2,3]. Dosing regimens
that require multiple daily dosing with diet considera-
tions and AR side effects have compromised the achieve-
ment of long-term HIV-1 suppression in infected patients
[4]. Additionally, the use of AR requires a concerted level
of commitment from the patient to prevent treatment fail-
ure due to resistance.
The CD4+ T lymphocyte is the major target for infection by
HIV-1. Cells of the mononuclear phagocyte system also
serve as a reservoir for HIV. Macrophages are a mature,
non-proliferating and immunologically active cells that
can be productively infected with HIV-1 and HIV-2 [5-8].
Altered cellular functions in the macrophage population
may contribute to the development and clinical progres-
sion of AIDS.
Evidence has accumulated that cells of the macrophage
lineage are vectors for the transmission of HIV-1. The pla-
cental macrophage is likely to be the primary cell type
responsible for vertical transmission of HIV-1 [9]. An
important property of HIV-1 for mucosal transmission is
the ability to infect macrophages [10]. Because of the
important role of cells of the monocytes/macrophage
(Mo/Mac) lineage in the pathogenesis of HIV-1, fully
effective AR must react with Mo/Mac in addition to other
targets.
Many promising compounds suffer from poor physio-
chemical properties leading to poor solubility and biodis-
tribution. Such properties limit drug-receptor interactions
to cause desired effects. For example, proteins and pep-
tides could be new drug candidates but suffer from low
oral absorption in the gastrointestinal tract and necessi-
tate daily subcutaneous administration. Nanoparticles
may be able to be administered parenterally but possibly
not daily. New drug candidates must demonstrate that
they reach the site of action and have a pharmacologic
effect. Special drug carrier systems and dosage forms such
as nanoparticles, hold the promise of overcoming obsta-
cles to bring about successful therapy [11]. Nanoparticles
are stable, solid colloidal particles consisting of macromo-
lecular material ranging in size from 10 to 1,000 nm.
Drugs can be adsorbed on the particle surface, entrapped
within the particle, or dissolved in the particle matrix
[12,13]. Nanoparticles represent an interesting carrier sys-
tem for the transport of antiviral drugs to Mo/Mac in an
attempt to reduce the required dose, minimize toxicity
and side effects, and improve the delivery of substances,
which have insufficient intracellular uptake.
Previous studies have demonstrated that AR can be
adsorbed onto a nanoparticle or microparticle carrier [14-
20]. These studies show that one antiretroviral drug can be
fabricated into nanoparticles as a drug delivery system.
This report shows the in vitro effect of fabricating nanopar-
ticles that contain ritonavir, lopinavir, and efavirenz for
sustained drug delivery. To the best of our knowledge, this
is the first study that attempts to fabricate three antiretro-
viral drugs in a polymeric nanoparticulate system.
Methods
Nanoparticle (NP) preparation
AR (ritonavir, lopinavir, efavirenz) was prepared using a
water-in-oil-in-water homogenization. Briefly, in a typical
procedure, AR drug powder (5 mg of each AR drug) was
added to poly-(lactic-co-glycolic acid) (PLGA) polymer
(molecular weight 110,000-139,000 Daltons (50 mg)) in
10 mL methylene chloride. The solution was heated in an
incubating shaker at 36°C and slowly stirred for a mini-
mum of 40-45 minutes. After the PLGA polymer was dis-
solved, it was drawn into a glass syringe and added in
drop-wise fashion to a solution of 0.25% w/v aqueous
solution of polyvinyl alcohol (PVA). A probe sonicator
(100 W for 6 min) (Sonicator XL, Misonix, Farmingdale,
NY) was used to homogenize the emulsion. The water-in-
oil emulsion that was formed was then placed in a glass
syringe and added to 30 mL of ethylene oxide/propylene
oxide block copolymer (Poloxamer-127; 2% [w/v] 30
mL); BASF, Mt. Olive, NJ) while the block copolymer was
being homogenized by the probe homogenizer as
described above for 15 minutes to form the water-in-oil-
in-water emulsion.
NPs containing osmium tetroxide, an electron-dense
agent, were formulated similarly, except that 10 mg of
osmium tetroxide, and one milligram of each AR was
added to the polymer solution and the procedure was fol-
lowed as above. Additionally, 6-hydroxycoumarin (a flu-
orescent dye; 100 μg) was added to the polymer solution
and one milligram of each AR was fabricated to make flu-
orescent NPs for flow cytometry and the procedure was
followed as above. In all formulation procedures, the
emulsion that was formed was stirred for a minimum of 4
hours at room temperature to evaporate the organic sol-
vent. The particles were rinsed twice with ddH2O to
remove PVA and unentrapped drugs followed by ultracen-
trifugation (15,000 G for 45 minutes at 4°C, Optima LE-
80K, Beckman, Palo Alto, CA), and then lyophilized (-
52°C and 5.62 torr; Labconco, Freezone 4.5) for 24 hours
to obtain a dry powder.BMC Infectious Diseases 2009, 9:198 http://www.biomedcentral.com/1471-2334/9/198
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Nanoparticle characterization
Nanoparticles were evaluated for size by zeta potential
and confirmed by scanning electron microscopy (SEM)
and surface change by using a zeta potential analyzer
(ZetaPlus, Brookhaven Instruments, Holtsville, NY). For
SEM, an aliquot of the fabricated nanoparticles, was sus-
pended in double-distilled water for a final concentration
of 0.2 mg/ml and an aliquot of suspended particles were
placed onto a scanning electron tip and sputter coated
with 2% w/v uranyl acetate, dried, and then visualized by
using a JEOL-40A (JEOL Ltd, Sheboygan, WI) scanning
electron microscope.
High-pressure liquid chromatography (HPLC)
HPLC was performed using a previously reported method
[21]. Briefly, the equipment included a pump (LC-
10ATvp), system controller (SIL-10ADvp); degasser unit
(DGU-14A), refrigerated auto-sampler (SIL-10ADvp);
and a UV-Vis detector (SPD-10ADvp) and a column
heater (set at 35°C) (all from Shimadzu Corporation,
Columbia, MD). Samples were run through a C18 pre-col-
umn and a Jupiter C18 reverse-phase [150 × 3.9 mm (I.D.)]
with 5 mm particle size packing (Phenomenex, Torrance,
CA). The mobile phase was 25 mM KHPO4 (pH 4.9) and
acetonitrile (40:60). The mobile phase was filtered and
degassed prior to use. Flow rate was set at 0.9 mL/min and
the detector was set at 212 nm. Samples of known
amounts of the AR drugs (lopinavir, ritonavir, and efa-
virenz) were diluted in methanol to obtain a 45-1000ng/
ml standard curve and then further diluted in PBS. Peak
area from the samples and standards were integrated
using EZ-Start chromatography software (Shimadzu) on a
Dell computer. Injection volume was 20 μL and all exper-
imental samples were analyzed in duplicate and averaged.
Standards were analyzed in triplicate and averaged. Tripli-
cate experiments were performed and all results are
reported as mean ± standard error of the mean (SEM).
One milligram of formed particles was dissolved in one-
milliliter methylene chloride to dissolve the NP, in glass
tubes and evaporated overnight in quadruplicate. High-
pressure liquid chromatography (HPLC) mobile phase
(200 μL) reconstituted the tubes for 5 minutes, the tubes
were vortexed for 1 minute. The tubes were centrifuged
(11,000 rpm, 10 minutes, 4°C) and aliquots were injected
into the HPLC equipment to determine AR drug loading,
loading efficiency, and entrapment efficiency. Inter-day
and intra-day variability was always < 10%.
Human monocytes isolation and cultivation
Human PBMCs were obtained from whole blood collec-
tion of HIV-1, -2 and hepatitis B seronegative donor and
purified using CPT Vacutainer tubes (B-D and Co., Sparks,
MD) according to the manufacturer instructions. Poly-
morphonuclear cells (1 × 106 cells/mL) were cultured in
DMEM supplemented with 10% heat-inactivated pooled
human serum, 1% glutamine, 1% penicillin-streptomy-
cin, and 10 μg/mL ciprofloxacin (Sigma Chemical Co)
then filter sterilized. The PBMCs were used within 2 hours
after blood collection. Cells were incubated at 37°C and
5% CO2. Media was one-half exchanged with fresh media
every 2-3 days. These cells were used for AR drug release
experiments from NPs as determined by HPLC.
Human PBMCs at 5 × 106  cells/mL were cultured in
DMEM supplemented with 10% heat-inactivated pooled
human serum, 1% glutamine, 1% penicillin-streptomy-
cin, and 10 μg/mL ciprofloxacin (Sigma Chemical Co),
and 1000 U/mL highly purified recombinant human mac-
rophage colony stimulating factor (M-CSF; R&D Systems,
Inc; Minneapolis, MN) for seven days to differentiate
monocyte-derived macrophages(MDM)[22]. Media was
one-half exchanged every 2-3 days. Monocyte-derived
macrophages were used for TEM and fluorescent imaging.
AR Release from Nanoparticles
Antiretroviral NPs (2 mg in 250 μL phosphate buffered
saline (PBS)) were added to PBMC cell culture flasks and
kept in the incubator. At specific times, media in the flask
was removed and placed in a sterile 15 mL conical tube
and centrifuged (400 × G, 24°C for 10 minutes) to pellet
the cells and the media was removed. Cell samples were
obtained every 2 hours for the first 8 hours, then 2, 3, 4,
6, 10, 14, 21, and 28 days. Cells (250 μL) were removed
from the tube and put into a microfuge tube for HPLC
analysis. Two hundred fifty microliters of 100% methanol
was added to the microfuge tube to lyse the cells, vortexed
for 1 minute and the cells were frozen (-20°C) until
assayed for AR drugs using HPLC. When HPLC was per-
formed, microfuge tubes were thawed, centrifuged at
15,000 rpm at 4°C for 10 minutes and an aliquot of
supernatant was placed into autosampler vials with glass
insert. Free drugs (25 μg/mL of each AR drug) was dis-
solved in HPLC-grade ethanol and then further diluted in
PBS, incubated with the PBMCs and cells were removed at
4, 8, 24, and 48 hours, lysed with methanol, centrifuged,
and assayed by HPLC as controls of these experiments.
Electron microscopy
To determine the shape and size of AR nanoparticles,
nanosuspensions were examined with a JEOL 40A scan-
ning electron microscope. NP shape and structural integ-
rity were examined in thin sections. For TEM, MDM were
exposed to AR nanoparticles at 5 × 10-6 M for 30 minutes
and 1 hour. Cells were rinsed with PBS, fixed with 2.5%
glutaraldehyde for 24 hours, post-fixed with 1% osmic
acid, dehydrated in graded ethanol solutions, and embed-
ded in Epon 812 mixture. Thin sections were cut and
stained with 2% uranyl acetate and examined under a
JEOL-1011.BMC Infectious Diseases 2009, 9:198 http://www.biomedcentral.com/1471-2334/9/198
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Analysis of fluorescent AR nanoparticle uptake
The ability of MDMs to uptake fluorescent AR nanoparti-
cles was assessed using FLOW cytometry analysis and
direct fluorescence microscopy. Chamber slides contain-
ing MDM (2.5 × 105) previously cultured had 25 μg of flu-
orescent AR nanoparticles in 50 μL PBS added to each well
for 30 and 60 minutes. MDMs cultured in the absence of
nanoparticles were used as controls. Following incuba-
tion, cultured MDM were rinsed with PBS and fixed in 4%
paraformaldehyde in PBS for 10 minutes and cover-
slipped. Cells were visualized with an inverted fluorescent
microscope (DMI4000B, Leica) and images were acquired
using Image ProPlus software (Media Cybernetics;
Bethesda, MD).
FLOW cytometry analysis used control and MDMs incu-
bated with fluorescent AR nanoparticles as above. These
cells were scraped from 6 well culture plates following
incubation, centrifuged for 2-4 minutes at 1,200 rpm,
rinsed in phosphate buffered saline (PBS), and fixed in
10% buffered formalin. Fixed cells were resuspended and
samples were run on a UV SORP FACSAria (BD Bio-
sciences, San Jose, CA). FLOW used 100 mW Coherent
Sapphire laser set at 488 nm for excitation and was
detected using a 530/30 bandpass filter (looking at light
between 515 nm and 545 nm).
Analysis of macrophage viability
MDM viability following exposure to and phagocytosis of
nanoparticles was measured by using the MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide)
method [23]. Active mitochondrial dehydrogenases in
healthy cells convert MTT generating water-insoluble, pur-
ple formazan crystals that are measured by spectrophoto-
metric techniques [24]. For each MTT assay, 2.5 × 105
differentiated human macrophages were plated on 24
well tissue culture plates using the media as previously
described. Macrophages were incubated with or without
AR nanoparticles immediately preceding and one hour
prior to application of MTT. MDMs were allowed to
metabolize MTT (5 mg/ml in DMEM supplemented
media) for 30 or 60 min at 37°C and 5% CO2. Media was
removed from cultured macrophages and cells were
treated with 100% dimethyl sulfoxide to lyse the cells and
dissolve formazan crystals. Lysates were transferred to 96
well plates for analysis. Absorbance of the lysate was
measured at 595 nm using a precision microplate reader
(Molecular Devices, model S/NE10984). Blank wells were
subtracted as background from each triplicate sample and
the samples were averaged.
Results
Antiretroviral nanoparticle size and particle charge (n = 9)
were measured after three batches. The particles averaged
(± SEM) 262 ± 83.9 and -11.4 ± 2.4, respectively. Figure 1
depicts the SEM photomicrograph of AR nanoparticles.
AR drugs were analyzed by HPLC for nanoparticle loading
and loading efficiency. Antiretroviral drug loading aver-
aged 4.9%, 5.2%, and 1.9% for RTV, LPV, and EFV, respec-
tively. Entrapment efficiency averaged 38%, 45%, and
86% for RTV, LPV, and EFV, respectively.
Osmium tetroxide ladened AR NPs were incubated with
macrophages for 0, 0.5, and 1 hour. Figures 2 show TEM
photomicrographs of osmium tetroxide ladened AR NPs
within macrophages as well as AR NPs undergoing phago-
cytosis.
Antiretroviral drug release from PLGA NPs incubated with
polymorphonuclear cells (PBMCs) is shown in Figure 3.
Scanning electron microscopy (SEM) of fabricated antiretro- viral nanoparticles (Mag × 7500) Figure 1
Scanning electron microscopy (SEM) of fabricated 
antiretroviral nanoparticles (Mag × 7500).
Transmission electron microscopy (TEM) of NPs in MDM Figure 2
Transmission electron microscopy (TEM) of NPs in 
MDM. Transmission electron microscopy (TEM) of nanopar-
ticles (NPs) within macrophages. Photos are high magnifica-
tion of MDM containing ART NPs (arrows; A) and control 
MDMs (B) ladened with osmium tetroxide after 45 minutes 
of incubation. Mag × 40,000.BMC Infectious Diseases 2009, 9:198 http://www.biomedcentral.com/1471-2334/9/198
Page 5 of 8
(page number not for citation purposes)
The inset figure is the HPLC analysis of the free drug incu-
bated with the PBMCs. Free drug incubated with PBMCs
demonstrate removal of AR drugs by day 2 in vitro. When
the cells were lysed and analyzed by HPLC, the free intra-
cellular concentrations of the three drugs peaked at 8
hours (RTV 5.1 ± 0.05; LPV 4.3 ± .03; and EFV 3.1 ± 0.02
μg) and were eliminated by 48 hours. In contrast, when
AR were fabricated into a NP and incubated in PBMCs,
intracellular AR peak concentrations were at 96 hours
(RTV 2.5 ± 1.1; LPV 4.1 ± 2.0 μg). Efavirenz intracellular
concentration peaked at 24 hours (12.6 ± 2.7 μg). All
three drugs continued to be released for 28 days. The 28
day concentrations for the three ARs were ≥ 0.9 μg.
6-Hydroxycoumarin was used to determine the efficiency
with which macrophages phagocytize fluorescent NPs.
Fluorescent macrophages were observed by FLOW cytom-
etry as well as by fluorescent microscopy. FLOW cytome-
try data shows that virtually all macrophages
phagocytized fluorescent NPs (data not shown). Direct
fluorescence showed the presence and relative localiza-
tion of nanoparticles in macrophages following incuba-
tion and uptake (Figure 4). While all imaged cells show
uptake of the fluorescent AR NPs, fluorescence is not seen
in control cells.
To address whether the uptake of AR NPs by macrophages
affected cell viability, MTT assays were performed (Figure
5). MTT assays measure the viability of cells by assessing
the presence of active mitochondrial dehydrogenases that
convert MTT into water-insoluble, purple formazan crys-
tals. Solubilization and analysis of formazan conversion
demonstrates that immediately following nanoparticle
addition and one hour after nanoparticle uptake the via-
bility of macrophages is not significantly different from
control conditions. Taken together these cellular assays
demonstrate that AR NPs are phagocytized by macro-
phages and uptake of AR nanoparticles does not interfere
with macrophage viability.
Discussion
The use of nanotechnology has exploded in the recent
years. Nanoparticles were initially developed as carriers
for vaccines and cancer chemotherapy agents [25-27]. The
use of nanotechnology as a drug delivery system has
mainly been investigated for the treatment of malignan-
cies. Nanoparticles can concentrate preferentially in
tumor masses, inflammatory sites, and infectious sites by
utilization of enhanced permeability and retention
(EPR)effect on the vasculature [28]. Modifying oncologic
drugs into nanoparticles and delivering the drug to the
malignant tissue has resulted in significant preliminary
results in animal models [29]. Indeed, this is where the
majority of research has been focused [30].
Other investigators have been able to fabricate single
antiretroviral drugs into a nanoparticle delivery system
[14-20]. However, the use of a single antiretroviral drug in
the treatment of HIV-1 only results in development of
resistant strains and treatment failures. Combination
drugs are currently the standard of practice for HIV-1 ther-
In vitro ART release from NPs incubated in PBMCs Figure 3
In vitro ART release from NPs incubated in PBMCs. 
Intracellular ritonavir, lopinavir, and efavirenz levels in 
PBMCs over time. The insert figure is the intracellular free 
drug levels in PBMCs over time.
Fluorescent NP uptake by human MDM Figure 4
Fluorescent NP uptake by human MDM. Fluorescent 
NP uptake by human MDM. A and B are control phase and 
fluorescent photomicrographs of human MDM in the 
absence of fluorescent NPs. Following 30 min incubation 
with NPs, MDM fluoresce due to NP uptake (C and D; 40× 
objective).BMC Infectious Diseases 2009, 9:198 http://www.biomedcentral.com/1471-2334/9/198
Page 6 of 8
(page number not for citation purposes)
apeutics. Our results demonstrate that three drugs can be
incorporated into a single nanoparticle for drug delivery.
The results of cellular assays show that macrophages
engulf these particles. This is advantageous, as HIV-1
requires host DNA replication for survival. Providing a
means to get significant drug concentrations intracellular
would inhibit the replication of HIV-1 in the reticuloen-
dothelial system (RES) where macrophages migrate. Fur-
ther studies are on going to determine this. Additionally,
preliminary MTT assay results show that PLGA particles
do not produce significant cellular toxicity. This is also
advantageous for development of these nanoparticles as a
drug delivery modality for human use. Taken together,
our data show that these inert particles are taken up by the
macrophages and have a sustained-release profile. The
results demonstrate the day 28 levels of AR drugs were ≥
0.9 μg within MDMs. This level is above the inhibitory
concentration (IC50) for wild-type virus for each of AR
drugs incorporated into these NPs. The IC50 for each of the
drugs against wild-type virus has been reported to be <
100 ng/ml. While further studies are necessary, this deliv-
ery system may have potential advantages.
Viral reservoirs within the body have prevented total erad-
ication of HIV-1 with successful AR [31]. A number of
studies have demonstrated persistent, low level HIV-1 rep-
lication in patients receiving oral highly active antiretrovi-
ral therapy (HAART) that renders them aviremic [32-34].
These studies provide evidence that continued viral repli-
cation occurs in lymphoid reservoirs. Our studies show
PLGA AR nanoparticles within the cytoplasm of macro-
phages. The PLGA AR nanoparticles are phagocytosized
by macrophages and these cells could deliver high AR lev-
els to lymphoid reservoirs and could positively affect per-
sistent, low level viral replication. This could prevent the
development of mutant HIV-1 virions to AR drugs. Fur-
ther research is necessary to determine the concentration
of AR drugs in these lymphoid reservoirs as well as gut-
associated lymphoid tissue (GALT) [35].
The results of these experiments demonstrate for the first
time that combination antiretroviral drugs can be loaded
efficiently into a nanoparticle drug delivery system. Our
data show that sustained drug release over the course of
28 days is possible. The goal of drug delivery systems is
cellular uptake and release with no cytotoxicity. Indeed,
this drug delivery system is advantageous as it could pre-
clude the need for daily administration of oral drugs to
maintain active concentrations in HIV-1 tissues with
lower total amount of drug exposure. Therefore, this
delivery method may be useful for patients that are non-
adherent to orally administered HAART and may offer
other patients treatment options. Additionally, since the
majority of the AR drugs are incorporated into the NP, the
amount of AR NPs necessary as dosage strength may be
lower. This could potentially reduce side effects that
patients currently have to tolerate for successful adher-
ence. Finally, if patients received ~100% of their AR drugs,
the development of resistance would slow and the efficacy
and durability of AR drug therapeutics would be
enhanced [36-38]. Of note, an investigational non-nucle-
otide reverse transcriptase inhibitor (NNRTI) capable of
once every 8 weeks administration has been recently pub-
lished showing that sustained delivery of antiretrovirals
may be utilized clinically [39]. Further studies are neces-
sary to produce reliable data regarding the pharmacology
and efficacy of this delivery system. These data provides
further evidence that sustained release of multiple AR
MTT assay results Figure 5
MTT assay results. Graphical representation of MTT assay 
for control macrophages (MDM) and MDMs incubated with 
nanoparticles. Nanoparticles and MTT substrate were imme-
diately added to the media of cultured human MDMs MTT 
assays were performed after 30 and 60 minutes (Panel A) of 
incubation. Alteratively, MDMs were incubated with and 
without nanoparticles for 1 hour before the MTT substrate 
was added and an MTT assay was performed after 30 and 60 
minutes (Panel B) of incubation.BMC Infectious Diseases 2009, 9:198 http://www.biomedcentral.com/1471-2334/9/198
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drugs from a nanoparticle drug delivery system present a
viable option for treatment of HIV-1.
Conclusion
The results of these experiments demonstrate that PLGA
polymer can be used to fabricate nanoparticles for combi-
nation AR to develop a drug delivery system that can be
used for IV administration to patients who are nonadher-
ent to their therapy. Furthermore, this delivery system has
prolonged release of combination AR for 28 days. The par-
ticles penetrate macrophages and do not cause toxicity to
these cells by MTT assay. Further study is necessary to
determine the drug concentrations in lymphoid tissue.
This could be a promising new delivery system for the
management of HIV-1 infected patients.
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